3 results
Approved WMORecruiting
Main objectives: The main aim of this study is twofold. We aim to (1) investigate whether rivastigmine can be used as a novel treatment to reduce ECT-induced interictal delirium and (2) to gain further insight into differences in determinants…
Approved WMOCompleted
The aim of this study is to determine NET availability in patients with neurodegenerative diseases to characterize NA system degeneration in people with Alzheimer's disease, Parkinson's disease (with and without dementia) and with…
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.